Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Investing

First patient dosed in Phase IIb imaging for Brain Mets

by admin April 28, 2025
April 28, 2025
First patient dosed in Phase IIb imaging for Brain Mets

Radiopharm Theranostics (RAD:AU) has announced First patient dosed in Phase IIb imaging for Brain Mets

Download the PDF here.

This post appeared first on investingnews.com

previous post
Silver Crown Royalties Announces Closing of Final Tranche of its Non-Brokered Private Placement
next post
Greenland’s prime minister says island cannot be bought, US has ‘not been respectful’

Related Posts

Crypto Market Recap: Trump’s Truth Social Moves to...

June 4, 2025

RUA GOLD Closes C$5.75 Million Brokered Offering Including...

February 21, 2025

Jim Thorne: US$5,000 Gold by 2028? “Crazy Phase”...

April 4, 2025

Uranium Stocks: 5 Biggest Companies in 2025

May 20, 2025

Crypto Market Update: SEC Pauses Bitwise ETF Conversion...

July 24, 2025

CG1 Non-renounceable Pro-rata Entitlement Offer

August 22, 2025

Byron King: Fear Trade in Play — Make...

April 3, 2025

CHARBONE Hydrogen Provides Update on Grid Interconnection with...

March 7, 2025

Walker Lane Resources Ltd. Announces Closing of Private...

July 24, 2025

Bold Ventures

June 14, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 2

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 3

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • 4

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 5

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 wallstreetwizardry.com | All Rights Reserved